Recombinant Mycobacterium Tuberculosis Fusion Protein(EC)(Anhui Zhifei Longcom Biologic Pharmacy)

Main objectives: (1) To investigate the sensitivity of EC in patients with tuberculosis aged 65 years and above (confirmed cases, clinically diagnosed cases); (2) To investigate the specificity of EC in healthy community population aged 65 years and above without other lung diseases; (3) To evaluate the safety of EC use in people aged 65 years and above. Secondary objectives: (1) To investigate the diagnostic results of EC at different judgment times (24 h, 48 h, 72 h) in the study population, analyze the interaction between the diagnosis time and the diagnostic criteria, evaluate the rationality of the diagnostic criteria (red halo and/or nodule), and optimize the judgment time and positive judgment criteria of the skin test results of this product; (2) To investigate the specificity of EC in community population aged 65 years and above with other non-tuberculous lung diseases; (3) To evaluate the correlation between EC and TB-PPD results in healthy community population aged 65 years and above without other lung diseases.